Last updated: October 2, 2026
Cetostearyl alcohol is a mature oleochemical excipient with stable pharmaceutical demand and broader exposure to cosmetics, dermatology, and personal care. Its financial profile is driven more by palm- and coconut-derived feedstock costs, energy, freight, plant utilization, and quality compliance than by patent exclusivity. Public companies generally do not report cetostearyl alcohol as a separate revenue line, so market value must be assessed through excipient volumes, oleochemical pricing, supplier portfolios, and downstream formulation demand.
What is cetostearyl alcohol and where is it used?
Cetostearyl alcohol, also called cetearyl alcohol, is a solid mixture of long-chain fatty alcohols, primarily cetyl alcohol and stearyl alcohol. It is used as an emollient, thickener, co-emulsifier, consistency agent, and stabilizer.
| Attribute |
Data |
| Common names |
Cetostearyl alcohol, cetearyl alcohol, cetylstearyl alcohol |
| Principal components |
Cetyl alcohol and stearyl alcohol |
| Common CAS reference |
67762-27-0 for cetearyl alcohol |
| Physical form |
White or nearly white waxy solid, flakes, pastilles, or pellets |
| Pharmaceutical functions |
Emollient, stiffening agent, co-emulsifier, viscosity modifier |
| Main dosage forms |
Creams, ointments, lotions, emulsions, topical gels, suppositories and selected oral formulations |
| Major end markets |
Pharmaceuticals, dermatology, cosmetics, skin care, hair care, personal care |
| Supply base |
Palm-derived, palm-kernel-derived, coconut-derived, and synthetic oleochemical routes |
Cetostearyl alcohol is often selected because it improves texture and emulsion stability at relatively low formulation cost. It can also reduce the need for multiple structuring agents in semisolid products.
How large is the cetostearyl alcohol market?
No major public company separately reports audited global revenue for cetostearyl alcohol. Market assessments therefore use a proxy consisting of pharmaceutical-grade fatty alcohol demand, personal-care consumption, excipient sales, and reported oleochemical capacity.
The market is best characterized as a high-volume, low-to-moderate value specialty chemical segment:
- Pharmaceutical-grade material represents a smaller volume share than cosmetics and personal care.
- Pharmaceutical-grade material commands a premium because of tighter impurity, microbial, traceability, documentation, and change-control requirements.
- Personal care is the largest demand pool and absorbs material that may not meet the highest pharmaceutical specifications.
- Demand is recurring because cetostearyl alcohol is consumed in everyday creams, lotions, ointments, cleansing products, and hair-care formulations.
- The product has limited substitution risk in mature formulations because replacing it can alter viscosity, spreadability, stability, and sensory performance.
The market's value growth is therefore more likely to track price and mix than rapid volume expansion. Pharmaceutical demand grows with topical drug delivery, dermatology, over-the-counter products, and generic semisolid formulations. Personal-care demand is more sensitive to consumer spending and regional economic conditions.
What drives cetostearyl alcohol pricing and margins?
Feedstock economics are the main price driver. Fatty alcohol producers are exposed to the cost of palm oil, palm-kernel oil, coconut oil, methanol, hydrogen, caustic chemicals, electricity, natural gas, and freight.
Key cost variables
| Driver |
Effect on cetostearyl alcohol economics |
| Palm and palm-kernel oil |
Changes raw-material cost for major oleochemical routes |
| Coconut oil |
Affects specialty and regional supply economics |
| Energy |
Influences hydrogenation, distillation, flaking, and utilities |
| Freight |
Has a material effect on delivered cost because supply is globally traded |
| Plant utilization |
Determines fixed-cost absorption and producer margins |
| Product purity |
Creates a premium for pharmaceutical and high-purity grades |
| Packaging |
Adds cost for drums, bags, lined cartons, and controlled handling |
| Certification |
Raises cost for GMP, sustainability, audit, and documentation programs |
Cetostearyl alcohol is generally less differentiated than complex specialty excipients. Pricing power is limited when several qualified producers can supply the same nominal grade. Suppliers gain stronger margins through pharmaceutical qualification, global regulatory support, sustainable sourcing, and reliable supply rather than through molecule-level exclusivity.
Which companies manufacture pharmaceutical-grade cetostearyl alcohol?
The competitive field includes integrated oleochemical producers, specialty excipient suppliers, and regional manufacturers. Companies active in related fatty alcohols or excipient grades include BASF, Croda, KLK OLEO, Sasol, VVF, Kao, Wilmar-linked oleochemical operations, and other Asian and European producers.
Representative commercial products and supplier capabilities include:
| Company or group |
Relevant capability |
| BASF |
Pharmaceutical excipients and fatty alcohol products, including Kolliwax product lines |
| Croda |
High-purity and specialty excipient materials with pharmaceutical documentation |
| KLK OLEO |
Integrated fatty alcohol and oleochemical production |
| Sasol |
Fatty alcohols and specialty chemical intermediates |
| VVF |
Fatty alcohols and personal-care raw materials |
| Kao |
Oleochemicals and fatty alcohol-related ingredients |
| Regional Asian producers |
Cost-competitive supply for pharmaceutical, cosmetic, and industrial grades |
Supplier qualification depends on more than chemical identity. Buyers typically evaluate certificate of analysis consistency, particle or flake characteristics, peroxide value, acid value, hydroxyl value, melting range, residual solvents, elemental impurities, microbial quality, packaging, change-control procedures, and audit history.
A manufacturer that supplies cosmetic grade cannot automatically replace a qualified pharmaceutical source. The drug-product manufacturer may need comparability data, stability assessment, regulatory notification, or customer approval before switching.
What is the FDA regulatory status of cetostearyl alcohol?
Cetostearyl alcohol is an excipient, not an active pharmaceutical ingredient. The U.S. Food and Drug Administration's Inactive Ingredient Database identifies inactive ingredients used in approved drug products by route and dosage form. Inclusion in the database does not create market exclusivity or establish a universal maximum concentration for every formulation.[1]
Its regulatory status is determined at the finished-product level. A sponsor must establish that the proposed amount and route are appropriate for the drug product and comply with applicable FDA requirements. The excipient itself is not approved through the abbreviated new drug application pathway as an active ingredient.
In Europe, pharmaceutical use is assessed under the European Pharmacopoeia framework and national or European medicines legislation. Excipients must meet applicable quality specifications, and manufacturers must account for excipient functionality, safety, supplier controls, and labeling requirements.[2][3]
Does cetostearyl alcohol have an Orange Book listing?
No. Cetostearyl alcohol is not an innovator drug with an Orange Book patent listing. The FDA Orange Book records approved drug products and certain listed patents or exclusivity information for those products. It does not create a patent estate for common excipients.[4]
Are there patents, Paragraph IV challenges, or biosimilar risks?
Cetostearyl alcohol has no meaningful molecule-level pharmaceutical patent barrier. The substance is a long-established mixture of fatty alcohols and is sold by multiple manufacturers.
| Legal issue |
Relevance to cetostearyl alcohol |
| Orange Book patents |
Not applicable to the excipient as a standalone substance |
| Paragraph IV litigation |
Not applicable to the excipient |
| Biosimilar competition |
Not applicable |
| Method-of-use patents |
Generally relevant only to a specific finished drug formulation |
| Formulation patents |
May cover a cream, ointment, emulsion, or delivery system using cetostearyl alcohol |
| Manufacturing patents |
May protect a producer's process, purification, feedstock treatment, or crystallization method |
| Trade secrets |
Relevant to quality optimization, process control, impurity management, and cost reduction |
A finished pharmaceutical product may have formulation patents that include cetostearyl alcohol. Those patents protect the composition or use of the drug product, not the general commercial supply of cetostearyl alcohol.
The primary intellectual-property risks concern proprietary manufacturing processes, supplier-specific grades, and formulation know-how. These protections can support a supplier relationship but rarely prevent procurement from an alternative qualified manufacturer.
How strong is the patent estate for cetostearyl alcohol?
The patent estate is weak for the base excipient and potentially stronger for selected processes or formulations.
Base substance
Cetostearyl alcohol is a commodity-like chemical mixture with broad commercial availability. Patent protection does not normally prevent competing producers from manufacturing equivalent material.
Manufacturing technology
Manufacturers may protect:
- Fatty alcohol purification and distillation methods
- Hydrogenation conditions
- Catalyst systems
- Color and odor reduction
- Low-peroxide or low-acid-value grades
- Particle engineering and flake formation
- Sustainable feedstock processing
- Contaminant removal
- Blending methods for specified cetyl-to-stearyl ratios
These rights can create operational advantages but usually do not establish durable exclusivity across the whole market.
Finished formulations
Pharmaceutical companies may claim specific concentration ranges, emulsion systems, topical delivery technologies, preservative combinations, or therapeutic uses involving cetostearyl alcohol. Generic applicants must evaluate those claims when seeking approval for the finished drug. The risk attaches to the product's formulation and labeling, not to the excipient supply market.
What formulations are protected by cetostearyl alcohol?
Cetostearyl alcohol is common in semisolid and topical formulations where it contributes to structure and stability.
Typical applications include:
- Corticosteroid creams and ointments
- Antifungal creams
- Emollient and barrier creams
- Dermatological lotions
- Vaginal and rectal preparations
- Sunscreens
- Moisturizers and medicated skin products
- Hair conditioners and cleansing products
- Selected oral emulsions and suspensions
Formulation developers may use cetostearyl alcohol with emulsifying waxes, glyceryl monostearate, polysorbates, carbomers, paraffin, petrolatum, mineral oils, silicones, and preservatives. A change in grade or supplier can affect droplet size, viscosity, melting behavior, phase separation, release rate, and patient acceptability.
What is the financial trajectory for cetostearyl alcohol suppliers?
The financial trajectory is stable but cyclical. Revenue growth is likely to come from three sources:
- Higher pharmaceutical and personal-care volumes.
- Price pass-through during feedstock inflation.
- Premiumization toward pharmaceutical, high-purity, sustainable, and traceable grades.
Margin expansion is more difficult. Integrated producers with captive feedstocks and large-scale plants generally have better cost positions than distributors or smaller standalone processors. Producers with pharmaceutical qualification can protect margins better than suppliers competing only on commodity price.
Financial outlook by period
| Period |
Expected market condition |
| Near term |
Volatility linked to palm, coconut, energy, freight, and inventory normalization |
| Medium term |
Low-single-digit volume growth in mature pharmaceutical and personal-care applications |
| Longer term |
Stable demand, with incremental growth from dermatology, skin care, and emerging-market drug manufacturing |
Public financial statements from diversified companies such as BASF, Croda, Sasol, KLK, and Kao aggregate relevant activities into broader segments. Cetostearyl alcohol revenue, gross margin, and operating profit are not normally disclosed separately. As a result, company-level financial analysis must use segment performance, fatty alcohol capacity, product mix, and oleochemical commentary rather than a standalone cetostearyl alcohol income statement.[5][6][7]
What manufacturing and intellectual-property barriers affect supply?
The main barriers are operational and regulatory rather than patent-based.
Manufacturing barriers
A producer must control:
- Raw-material consistency
- Fatty alcohol chain-length distribution
- Melting range
- Color, odor, and oxidation
- Residual catalysts and solvents
- Microbial contamination
- Flake or pellet geometry
- Packaging and warehouse conditions
- Batch-to-batch reproducibility
Pharmaceutical customers may require supplier audits, quality agreements, validated analytical methods, notification of changes, and long-term stability data. These requirements create switching costs even when the chemistry is simple.
Geographic coverage
Asia remains central to global oleochemical production because of palm and palm-kernel feedstock availability, processing capacity, and export infrastructure. Europe and North America remain important for pharmaceutical-grade finishing, specialty excipients, formulation development, distribution, and regulatory support.
Regional supply risk can arise from:
- Export restrictions
- Crop disruptions
- Port congestion
- Energy shortages
- Environmental regulation
- Sustainability certification requirements
- Currency movements
- Concentration of production in Southeast Asia
Sustainability standards such as RSPO certification can affect supplier selection and procurement premiums, particularly for multinational pharmaceutical and consumer-health companies.[8]
What competitive risks exist for generic drug manufacturers?
Generic manufacturers face limited risk from excipient exclusivity but meaningful risk from formulation performance and supply continuity.
A supplier change can trigger:
- Comparative laboratory testing
- Pilot-scale batches
- Stability studies
- Process revalidation
- Regulatory assessment
- Customer or authority notification
- New technical agreements
For simple topical products, multiple cetostearyl alcohol suppliers may be available. For complex emulsions, a particular grade can become functionally critical. The commercial risk is therefore qualification-related rather than patent-related.
Generic manufacturers should maintain at least one qualified alternate source where feasible, monitor fatty alcohol specifications, and distinguish between pharmaceutical-grade, cosmetic-grade, and technical-grade material.
How does cetostearyl alcohol compare with competing excipients?
| Excipient |
Primary role |
Relative differentiation |
Main substitution issue |
| Cetostearyl alcohol |
Structuring agent, emollient, co-emulsifier |
Low to moderate |
Changes in viscosity, texture, and emulsion stability |
| Glyceryl monostearate |
Emulsifier and consistency agent |
Moderate |
Different melting and interfacial behavior |
| Stearic acid |
Thickener and emollient |
Low |
Can alter pH, crystallization, and skin feel |
| Cetyl alcohol |
Emollient and viscosity modifier |
Low |
Lower or different chain-length profile |
| Carbomer |
High-efficiency rheology modifier |
Moderate |
Requires neutralization and has different release behavior |
| Beeswax |
Natural structuring agent |
Moderate |
Greater variability and different sensory properties |
| Paraffin or petrolatum |
Occlusive base |
Low |
Does not replicate emulsification or texture contribution |
Cetostearyl alcohol remains competitive because it combines low cost, broad availability, formulation familiarity, and predictable performance.
What licensing deals and commercial partnerships affect the market?
There is no widely reported licensing structure comparable to patented active pharmaceutical ingredients. Commercial arrangements typically take the form of:
- Long-term supply agreements
- Distribution contracts
- Private-label manufacturing
- Pharmaceutical excipient qualification programs
- Sustainability-linked sourcing agreements
- Technical-service arrangements
- Toll manufacturing
- Regional agency relationships
These agreements can create customer-specific supply positions but generally do not prevent rival producers from selling equivalent material. Contract value depends on volume commitments, quality obligations, change-control rights, delivery terms, and feedstock pass-through provisions.
What is the generic launch and revenue exposure outlook?
For drug manufacturers, cetostearyl alcohol is rarely the principal determinant of generic launch timing. The greater commercial exposure lies in products where the excipient is functionally important and the formulation is difficult to reproduce.
Revenue exposure is highest in:
- High-volume dermatology products
- Hospital and institutional creams
- Consumer-health skin products
- Large generic portfolios using common semisolid platforms
- Products with narrow texture or release specifications
For excipient producers, revenue exposure is spread across pharmaceuticals, personal care, cosmetics, and industrial applications. This diversification reduces dependence on any single drug product but also limits the ability to pass through pharmaceutical-grade premiums across the entire portfolio.
Key Takeaways
- Cetostearyl alcohol is a mature, widely available excipient with stable pharmaceutical demand.
- Cosmetics and personal care account for a larger demand base than pharmaceuticals.
- Feedstock, energy, freight, and plant utilization drive financial performance.
- Pharmaceutical-grade material earns a premium through quality systems, documentation, and customer qualification.
- The excipient has no meaningful standalone Orange Book, Paragraph IV, or biosimilar exposure.
- Patent risk is concentrated in manufacturing processes and finished-product formulations.
- Public companies do not generally disclose cetostearyl alcohol revenue separately.
- The medium-term outlook is stable, with modest volume growth and cyclical pricing.
- Supply continuity, grade consistency, and regulatory qualification are more important than patent exclusivity.
- Integrated oleochemical producers and suppliers with pharmaceutical-grade infrastructure have the strongest competitive positions.
FAQs about cetostearyl alcohol market and pharmaceutical supply
Is cetostearyl alcohol the same as cetearyl alcohol?
Yes. Cetostearyl alcohol and cetearyl alcohol are commonly used names for a mixture containing mainly cetyl and stearyl alcohol.
Is cetostearyl alcohol safe in pharmaceutical creams?
It is widely used in topical and cosmetic products, but safety and suitability depend on concentration, route, formulation, impurities, and the finished product's regulatory assessment.
Can a pharmaceutical company change its cetostearyl alcohol supplier?
Yes, but the change may require comparability testing, stability work, quality-system review, and regulatory assessment.
Does cetostearyl alcohol have a DMF?
A supplier may maintain a Drug Master File or equivalent regulatory package for a pharmaceutical-grade product, but DMF availability is supplier-specific and does not apply automatically to every commercial grade.
Will palm-oil regulation affect cetostearyl alcohol pricing?
Yes. Palm and palm-kernel feedstock costs, sustainability requirements, certification premiums, export policy, and supply disruptions can affect both price and availability.
Can cetostearyl alcohol be replaced by stearic acid?
Sometimes, but the replacement can change emulsion stability, viscosity, melting behavior, skin feel, and drug-release performance. Reformulation and stability evaluation are generally required.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.
-
European Medicines Agency. (2018). Guideline on excipients in the label and package leaflet of medicinal products for human use. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
BASF SE. (2023). Annual report 2023. https://www.basf.com/
-
Croda International Plc. (2023). Annual report and accounts 2023. https://www.croda.com/
-
Sasol Limited. (2023). Integrated report 2023. https://www.sasol.com/
-
Roundtable on Sustainable Palm Oil. (2024). Principles and criteria for the production of sustainable palm oil. https://rspo.org/
